Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of Once Daily TETA 4HCL vs Cuprior® in Healthy Participants
NCT06128954Phase 1Completed
- Sponsor
- Orphalan
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trientine tetrahydrochloride in Wilson's disease (2 arms), sponsored by Orphalan. Primary endpoints: Area Under the Curve of TETA 4HCL up to 48 hours, Area Under the Curve of N1-acetyltriethylenetetramine up to 48 hours and 7 more. Started Jan 2024; status: completed.
02
Drugs
trientine tetrahydrochloride
03
Conditions
Wilson's disease
Beyond the preview
Go deeper on NCT06128954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128954.